Posted by Michael Wonder on 26 Nov 2021
Health Canada issues Notice of Compliance for Trodelvy, a new treatment option for an aggressive type of metastatic breast cancer
25 November 2021 - Trodelvy significantly reduced the risk of death by 49% compared with single agent chemotherapy in the Phase 3 ASCENT trial.
Gilead Sciences Canada today announced that Health Canada has granted Notice of Compliance to Trodelvy (sacituzumab govitecan) for the treatment of adult patients with unresectable locally advanced or metastatic triple negative breast cancer who have received two or more prior therapies, at least one of them for metastatic disease.
